Forma Medical Issued Key Methods Patent

Forma Medical Inc. is centering its business strategy on OptimalMTP, a procedural innovation for achieving the minimally invasive plating of the first metatarsophalangeal (MTP) joint fusion. This strategic refocus is being partly facilitated by a newly-issued patent.

OptimalMTP’s commercial growth has accelerated since its launch, with demonstrated clinical success in more than 650 patients. Building on this clinical and commercial momentum, Forma Medical is prioritizing its resources to ensure continued growth of the OptimalMTP procedure. The company is convinced this focus will accelerate surgeon adoption, deepen clinical evidence, and establish OptimalMTP as the category-defining solution for MTP fusion.

In line with its OptimalMPT focus, Forma Medical has been issued U.S. Patent No. 12,521,157, which secures broad method claims covering minimally invasive joint fixation with a low-profile plating construct delivered through limited incisions, thereby protecting critical procedural innovations. These methods enable surgeons to apply the gold-standard plate-and-screw construct using minimally invasive techniques, aligning trusted surgical biomechanics with modern patient expectations.

“This patent protects the technology that allows surgeons to achieve both minimally invasive procedures and decades of proven biomechanics: exactly what our mission is about,” Forma Medical CEO Andrew C. Davison said. “OptimalMTP brings these two critical goals together, and the strong clinical adoption shows how much this capability is needed.”

Building on this momentum, the company has appointed Aaron Smith to its Board of Directors. Smith has more than two decades of leadership experience in orthopedic medical devices. He most recently served as CEO of Artelon, which was acquired by Stryker Corp., and has a proven track record of advancing patient care, driving commercial adoption, and navigating strategic transactions.

“With a sharpened strategic focus and the addition of Aaron Smith to our board, Forma is well positioned to lead the evolution in MTP fusion,” Davison added.

Forma Medical will showcase its latest advancements at the upcoming American College of Foot and Ankle Surgeons (ACFAS) Annual Scientific Conference in Las Vegas (Feb. 23–27).

Forma Medical Inc. is a privately held orthopedic device company developing differentiated solutions that combine strong biomechanical principles with minimally invasive surgical techniques. The company’s flagship OptimalMTP system is designed to advance the standard of care in first MTP joint fusion by delivering stability, reproducibility, and efficiency through an MIS approach.